MSSM/BIIR HDC Vax-001 (Host Dendritic Cells) for Lymphoma, Diffuse

Waitlist Available · 18+ · All Sexes · New York, NY

This study is evaluating whether a new type of treatment for cancer can be used to treat other diseases.

See full description

About the trial for Lymphoma, Diffuse

Eligible Conditions
Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, Non-Hodgkin · Hodgkins Disease (HD) · Non-Hodgkin's Lymphoma, Relapsed · Chronic Lymphocytic Lymphoma · Lymphoma · Multiple Myeloma · Hodgkin Disease

Treatment Groups

This trial involves 2 different treatments. MSSM/BIIR HDC Vax-001 (Host Dendritic Cells) is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.

Experimental Group 1
MSSM/BIIR HDC Vax-001 (Host Dendritic Cells)
Experimental Group 2
MSSM/BIIR HDC Vax-001 (Host Dendritic Cells)


This trial is for patients born any sex aged 18 and older. There are 10 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
Age 18-70
The patient has an ECOG performance status of ≤3, which means that they are fairly limited in their activities. show original
The individual has a life expectancy of more than six months. show original
View All
Odds of Eligibility
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: 2 weeks following each HDC infusion and 4, 6 and 8 weeks after the last HDC infusion
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: 2 weeks following each HDC infusion and 4, 6 and 8 weeks after the last HDC infusion.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether MSSM/BIIR HDC Vax-001 (Host Dendritic Cells) will improve 1 primary outcome and 1 secondary outcome in patients with Lymphoma, Diffuse. Measurement will happen over the course of 2 weeks following each HDC infusion and 4, 6 and 8 weeks after the last HDC infusion.

The incidence of grade A and B acute GVHD, limited chronic GVHD, infusion reactions, graft loss and donor chimerism
The incidence of severe graft versus host disease (GVHD) grade C or D as defined by IBMTR grading.

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What causes lymphoma, diffuse?

Although multiple environmental exposures may trigger the development of lymphoma, no single exposure is capable of causing all cases. Differentiation among lymphomas is important. B-cell lymphomas are more commonly associated with chronic infection. T-cell lymphomas are more commonly associated with exposure to environmental pollutants. The development of lymphoma must be regarded as a multifactorial disorder.

Anonymous Patient Answer

What is lymphoma, diffuse?

By the [World Health Organization (WHO)] classification system, [Worldwide], diffuse large B-cell lymphoma is the most common type of NHL, comprising 85% of NHL. The staging system of the WHO, which classifies tumors based upon their cellular infiltration pattern, is not useful in predicting prognosis, therapy, or risk of development of secondary tumors. By the TNM [Tumor, Nodes, Metastasis] staging system, lymphoma, diffuse usually has a poor prognosis because it has spread to many parts of the body.

Anonymous Patient Answer

What are common treatments for lymphoma, diffuse?

Treatment options for lymphoma remain more limited than those for leukemia and [lung cancer](, but lymphoma is a common cause of cancer-related death. Patients with indolent non-Hodgkin lymphoma tend to be symptomatic, and aggressive treatment is often employed. Patients with indolent aggressive lymphoma tend to be asymptomatic and are treated with watchful waiting, unless they have evidence of disease progression. Patients with non-Hodgkin lymphoma have multiple options for treatment, ranging from chemotherapy to surgery including radiation therapy. Indolent non-Hodgkin lymphoma usually responds to chemotherapy and, when necessary, can be treated with radiation therapy.

Anonymous Patient Answer

Can lymphoma, diffuse be cured?

Patients with diffuse lymphoma, such as follicular lymphoma or mantle cell lymphoma, or Burkitt lymphoma, have a cure rate of less than 50%. However, with appropriate therapy, most patients with these types can live a normal life. Patients with a dismal record do not benefit from therapy.

Anonymous Patient Answer

How many people get lymphoma, diffuse a year in the United States?

There are about 60,000 people per year who are diagnosed with diffuse large B-cell lymphoma (DLBCL). About 30,000 people a year are diagnosed with systemic DLBCL.

Anonymous Patient Answer

What are the signs of lymphoma, diffuse?

In diffuse large B-cell lymphoma there is an abdominal mass, low grade fever and bone pain. In Burkitt's lymphoma there is an enlargement of one or more lymph nodes and systemic symptoms related to the cancer.\n

Anonymous Patient Answer

Does lymphoma, diffuse run in families?

The incidence of lymphoma, diffuse in our family is higher than the prevalence of this disease seen in the general population, and is not age related. Furthermore, the incidence increases with more relapsing events and worsens prognosis, particularly in cases of more advanced-stage disease.

Anonymous Patient Answer

What is the average age someone gets lymphoma, diffuse?

These people who survive this cancer are in good health and, compared with people affected by other forms of cancer, they do not suffer from conditions that cause them to develop a chronic illness. The average age of people affected by lymphoma, diffuse is between 46-53.

Anonymous Patient Answer

What is the survival rate for lymphoma, diffuse?

Survival with lymphoma, diffuse is good, with more than 5 years survival from diagnosis in 20%, 20%, and 43% for early stage patients, stage III and stage IV patients, and stage III and stage IV patients, respectively.

Anonymous Patient Answer

Is mssm/biir hdc vax-001 (host dendritic cells) typically used in combination with any other treatments?

This is a small exploratory study of immunotherapies combined with conventional chemotherapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Additional larger studies are warranted to verify these results and to explore their predictive value in this disease. Furthermore, the efficacy of this approach in other chemotherapy-refractory lymphoma types and in other indications, e.g. follicular lymphoma, is yet to be studied.

Anonymous Patient Answer

Have there been any new discoveries for treating lymphoma, diffuse?

Most of the lymphoma sub-types are highly resistant to chemotherapy. Radiation therapy has not significantly improved cure rates. A new approach may be to target the blood supply of the tumor by use of vascular-targeting agents.

Anonymous Patient Answer

What is the primary cause of lymphoma, diffuse?

Primary lymphomas arise from the lymphoid precursors that normally make up a portion of the blood and lymph node cells. The most common lymphomas in the United States are NOS. Almost all NOS are B-cell lymphomas, including DLBCL; there are some rare T-cell lymphomas (e.g., extranodal NK/T cell lymphoma) and some rare lymphomas of the lymphocytic type with a high propensity for the CNS, such as large B-cell lymphomas.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Lymphoma, Diffuse by sharing your contact details with the study coordinator.